Management of chronic myeloid leukemia in blast crisis

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis

(2014) H Jiang et al.   BONE MARROW TRANSPLANTATION

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

(2014) R Kihara et al.   LEUKEMIA

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

(2013) Ohad Benjamini et al.   AMERICAN JOURNAL OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

(2013) Paolo Strati et al.   CANCER

Advances in Immunotherapy of Chronic Myeloid Leukemia CML

(2013) Stefanie Erika Held et al.   CURRENT CANCER DRUG TARGETS

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

(2013) David Ghez et al.   EUROPEAN JOURNAL OF CANCER

Enhanced SH3/Linker Interaction Overcomes Abl Kinase Activation by Gatekeeper and Myristic Acid Binding Pocket Mutations and Increases Sensitivity to Small Molecule Inhibitors

(2013) Shoghag Panjarian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

(2013) Elias J. Jabbour et al.   LEUKEMIA & LYMPHOMA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat CML blast crisis

(2012) R. Hehlmann   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

The EBMT activity survey: 1990–2010

(2012) J R Passweg et al.   BONE MARROW TRANSPLANTATION

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

(2011) D. Milojkovic et al.   HAEMATOLOGICA

Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

(2011) Nitin Jain et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

(2011) F J Giles et al.   LEUKEMIA

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

(2011) V Grossmann et al.   LEUKEMIA

Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib

(2010) Baijun Fang et al.   ANNALS OF HEMATOLOGY

Capnocytophaga canimorsus sepsis

(2010)   BLOOD

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study

(2010) Giuseppe Saglio et al.   CANCER

Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine

(2010) Antonella Perotti et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

(2010) Bénédicte Deau et al.   LEUKEMIA RESEARCH

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

(2010) Jianming Zhang et al.   NATURE

The blast phase of chronic myeloid leukaemia

(2009) Richard T. Silver   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

(2009) R. T. Silver et al.   HAEMATOLOGICA

Treatment of chronic myeloid leukemia in blast crisis

(2008) R. Hehlmann et al.   HAEMATOLOGICA

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

(2008) F. Palandri et al.   HAEMATOLOGICA

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

(2008) J Cortes et al.   LEUKEMIA